(Q33488506)

27 July 2017

Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study (English)

1 reference

27 July 2017

Carboplatin in Combination with Epirubicin and Cyclophosphamide in Patients with Advanced Ovarian Cancer: A phase II study (English)

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

18 May 2024

1 reference

H. Andersson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7576751

18 May 2024

L. G. Friberg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7576751

18 May 2024

G. Horvath

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7576751

18 May 2024

O. Johansson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7576751

18 May 2024

M. Akesson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7576751

18 May 2024

R. Westberg

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7576751

18 May 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7576751

18 May 2024

publication date

1 January 1995

1 reference

27 July 2017

1 reference

27 July 2017

34

1 reference

27 July 2017

6

1 reference

27 July 2017

821-827

1 reference

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

27 July 2017

1 reference

https://api.crossref.org/works/10.3109%2F02841869509127192

A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841869509127192

A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841869509127192

Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841869509127192

Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841869509127192

New cytotoxic drugs in treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841869509127192

Treatment of advanced ovarian cancer: a randomised trial comparing adriamycin or 4'epi-adriamycin in combination with cisplatin and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841869509127192

Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer

21 January 2018

1

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma

18 May 2024

2

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study

18 May 2024

3

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin, and cisplatin

18 May 2024

4

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer

18 May 2024

5

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

18 May 2024

7

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

18 May 2024

9

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. GICOG (Gruppo Interregionale Cooperativo Oncologico Ginecologia), Italy

18 May 2024

10

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma

18 May 2024

11

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

18 May 2024

12

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group

18 May 2024

15

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

18 May 2024

19

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. A multicenter trial

18 May 2024

22

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer

18 May 2024

24

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial

18 May 2024

25

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

18 May 2024

26

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer

18 May 2024

27

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

18 May 2024

28

1 reference

https://api.crossref.org/works/10.3109/02841869509127192

18 May 2024

Identifiers

1 reference

27 July 2017

1 reference